KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox/flox) model

C-C Weng, J R Hawse, M Subramaniam, V H S Chang, W C Y Yu, W-C Hung, L-T Chen, K-H Cheng

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Krüppel-like transcription factor 10 (KLF10), also named as TIEG1, plays essential roles in mediating transforming growth factor beta (TGFβ) signaling and has been shown to function as a tumor suppressor in multiple cancer types. However, its roles in mediating cancer progression in vivo have yet to be fully characterized. Here, we have employed two well-characterized Pdx-1CreLSL-Kras(G12D) and Pdx-1CreLSL-Kras(G12D)p53(L/L) pancreatic cancer models to ablate KLF10 expression and determine the impact of KLF10 deletion on tumor development and progression. We show that loss of KLF10 cooperates with Kras(G12D) leading to an invasive and widely metastatic phenotype of pancreatic ductal adenocarcinoma (PDAC). Mechanistically, loss of KLF10 in PDAC is shown to increase distant metastases and cancer stemness through activation of SDF-1/CXCR4 and AP-1 pathways. Furthermore, we demonstrate that targeting the SDF-1/CXCR4 pathway in the context of KLF10 deletion substantially suppresses PDAC progression suggesting that inhibition of this pathway represents a novel therapeutic strategy for PDAC treatment.

Original languageEnglish
Pages (from-to)5532-5543
Number of pages12
JournalOncogene
Volume36
Issue number39
DOIs
Publication statusPublished - Sep 28 2017

Fingerprint

Pancreas
Adenocarcinoma
Transcription Factors
Neoplasm Metastasis
Neoplasms
Transcription Factor AP-1
Pancreatic Neoplasms
Transforming Growth Factor beta
Phenotype
Therapeutics

Keywords

  • Animals
  • Carcinoma, Pancreatic Ductal
  • Chemokine CXCL12
  • Early Growth Response Transcription Factors
  • Humans
  • Kruppel-Like Transcription Factors
  • Mice
  • Mice, Inbred C57BL
  • Neoplasm Metastasis
  • Pancreatic Neoplasms
  • Proto-Oncogene Proteins p21(ras)
  • Signal Transduction
  • Survival Rate
  • Tumor Suppressor Protein p53
  • Journal Article

Cite this

KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox/flox) model. / Weng, C-C; Hawse, J R; Subramaniam, M; Chang, V H S; Yu, W C Y; Hung, W-C; Chen, L-T; Cheng, K-H.

In: Oncogene, Vol. 36, No. 39, 28.09.2017, p. 5532-5543.

Research output: Contribution to journalArticle

Weng, C-C ; Hawse, J R ; Subramaniam, M ; Chang, V H S ; Yu, W C Y ; Hung, W-C ; Chen, L-T ; Cheng, K-H. / KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox/flox) model. In: Oncogene. 2017 ; Vol. 36, No. 39. pp. 5532-5543.
@article{87398de5ceb349fa8d66c9a5153c893d,
title = "KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox/flox) model",
abstract = "Kr{\"u}ppel-like transcription factor 10 (KLF10), also named as TIEG1, plays essential roles in mediating transforming growth factor beta (TGFβ) signaling and has been shown to function as a tumor suppressor in multiple cancer types. However, its roles in mediating cancer progression in vivo have yet to be fully characterized. Here, we have employed two well-characterized Pdx-1CreLSL-Kras(G12D) and Pdx-1CreLSL-Kras(G12D)p53(L/L) pancreatic cancer models to ablate KLF10 expression and determine the impact of KLF10 deletion on tumor development and progression. We show that loss of KLF10 cooperates with Kras(G12D) leading to an invasive and widely metastatic phenotype of pancreatic ductal adenocarcinoma (PDAC). Mechanistically, loss of KLF10 in PDAC is shown to increase distant metastases and cancer stemness through activation of SDF-1/CXCR4 and AP-1 pathways. Furthermore, we demonstrate that targeting the SDF-1/CXCR4 pathway in the context of KLF10 deletion substantially suppresses PDAC progression suggesting that inhibition of this pathway represents a novel therapeutic strategy for PDAC treatment.",
keywords = "Animals, Carcinoma, Pancreatic Ductal, Chemokine CXCL12, Early Growth Response Transcription Factors, Humans, Kruppel-Like Transcription Factors, Mice, Mice, Inbred C57BL, Neoplasm Metastasis, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Signal Transduction, Survival Rate, Tumor Suppressor Protein p53, Journal Article",
author = "C-C Weng and Hawse, {J R} and M Subramaniam and Chang, {V H S} and Yu, {W C Y} and W-C Hung and L-T Chen and K-H Cheng",
year = "2017",
month = "9",
day = "28",
doi = "10.1038/onc.2017.155",
language = "English",
volume = "36",
pages = "5532--5543",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "39",

}

TY - JOUR

T1 - KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox/flox) model

AU - Weng, C-C

AU - Hawse, J R

AU - Subramaniam, M

AU - Chang, V H S

AU - Yu, W C Y

AU - Hung, W-C

AU - Chen, L-T

AU - Cheng, K-H

PY - 2017/9/28

Y1 - 2017/9/28

N2 - Krüppel-like transcription factor 10 (KLF10), also named as TIEG1, plays essential roles in mediating transforming growth factor beta (TGFβ) signaling and has been shown to function as a tumor suppressor in multiple cancer types. However, its roles in mediating cancer progression in vivo have yet to be fully characterized. Here, we have employed two well-characterized Pdx-1CreLSL-Kras(G12D) and Pdx-1CreLSL-Kras(G12D)p53(L/L) pancreatic cancer models to ablate KLF10 expression and determine the impact of KLF10 deletion on tumor development and progression. We show that loss of KLF10 cooperates with Kras(G12D) leading to an invasive and widely metastatic phenotype of pancreatic ductal adenocarcinoma (PDAC). Mechanistically, loss of KLF10 in PDAC is shown to increase distant metastases and cancer stemness through activation of SDF-1/CXCR4 and AP-1 pathways. Furthermore, we demonstrate that targeting the SDF-1/CXCR4 pathway in the context of KLF10 deletion substantially suppresses PDAC progression suggesting that inhibition of this pathway represents a novel therapeutic strategy for PDAC treatment.

AB - Krüppel-like transcription factor 10 (KLF10), also named as TIEG1, plays essential roles in mediating transforming growth factor beta (TGFβ) signaling and has been shown to function as a tumor suppressor in multiple cancer types. However, its roles in mediating cancer progression in vivo have yet to be fully characterized. Here, we have employed two well-characterized Pdx-1CreLSL-Kras(G12D) and Pdx-1CreLSL-Kras(G12D)p53(L/L) pancreatic cancer models to ablate KLF10 expression and determine the impact of KLF10 deletion on tumor development and progression. We show that loss of KLF10 cooperates with Kras(G12D) leading to an invasive and widely metastatic phenotype of pancreatic ductal adenocarcinoma (PDAC). Mechanistically, loss of KLF10 in PDAC is shown to increase distant metastases and cancer stemness through activation of SDF-1/CXCR4 and AP-1 pathways. Furthermore, we demonstrate that targeting the SDF-1/CXCR4 pathway in the context of KLF10 deletion substantially suppresses PDAC progression suggesting that inhibition of this pathway represents a novel therapeutic strategy for PDAC treatment.

KW - Animals

KW - Carcinoma, Pancreatic Ductal

KW - Chemokine CXCL12

KW - Early Growth Response Transcription Factors

KW - Humans

KW - Kruppel-Like Transcription Factors

KW - Mice

KW - Mice, Inbred C57BL

KW - Neoplasm Metastasis

KW - Pancreatic Neoplasms

KW - Proto-Oncogene Proteins p21(ras)

KW - Signal Transduction

KW - Survival Rate

KW - Tumor Suppressor Protein p53

KW - Journal Article

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85031917666&origin=resultslist&sort=plf-f&src=s&sid=28ffb2dae9e7f46b25002303b553b9f4&sot=a&sdt=a&sl=17&s=AU-ID%287407521534%29&relpos=2&citeCnt=0&searchTerm=

U2 - 10.1038/onc.2017.155

DO - 10.1038/onc.2017.155

M3 - Article

C2 - 28581520

VL - 36

SP - 5532

EP - 5543

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 39

ER -